GHK-Cu (copper tripeptide-1)
Also referred to as Copper tripeptide-1, Glycyl-L-histidyl-L-lysine copper.
Status: Cosmetic or topical context. GHK-Cu appears widely in topical cosmetic formulations. Cosmetic ingredients are not reviewed by the FDA for medical benefit, and a cosmetic listing is not an approval. Any compounded topical preparation is a separate matter that a licensed pharmacy and the prescribing physician assess individually.
GHK-Cu is a small naturally occurring copper-binding peptide that appears in human plasma and in many topical cosmetic products. Most published work concerns skin appearance and laboratory measures of skin biology, and study sizes are generally small. It is a cosmetic ingredient rather than an FDA-approved medicine, so claims about medical benefit are not supported by an approval pathway.
How it is described in the literature
GHK-Cu binds copper and has been described in laboratory work as influencing gene expression related to skin matrix proteins. Findings from cell culture and small topical studies describe changes in measured skin properties. Whether those measures translate into results a person notices depends on the formulation, the concentration used in the study, and the population, and it varies between studies.
What researchers and clinicians are studying
- Topical formulations and measured skin firmness or texture in small studies
- Laboratory measures of skin matrix protein expression
- Copper transport biology and its role in skin
- Tolerability of topical copper peptide products
What is not established
- Large, independent, long-duration human trials are lacking for most marketed claims
- Comparative superiority against established topical actives such as retinoids has not been demonstrated
- Effects on hair density are studied far less rigorously than the marketing around them suggests
- Injectable use is not supported by the cosmetic evidence base and is a separate question entirely
Safety and eligibility
- Topical copper peptides are generally well tolerated in the published literature, though irritation and contact reactions occur
- Layering multiple active topicals can increase irritation, so sequencing matters
- People with copper metabolism disorders should raise this with a physician before use
How eligibility is evaluated
- A physician reviews your skin history, current topicals, and any prior reactions
- Expectations are set against what the published evidence supports rather than marketing copy
- If a prescription topical with stronger evidence fits your goal better, the physician will recommend that instead
Generally not appropriate for
- Anyone with a known copper allergy or a copper metabolism disorder, absent specialist input
- Application to broken skin, active infection, or an undiagnosed lesion
- Anyone using it in place of evaluation for a changing or suspicious skin lesion
Frequently asked questions
Is GHK-Cu a drug?
In its common topical form it is used as a cosmetic ingredient, not an approved drug. Cosmetic ingredients are not reviewed by the FDA for medical benefit, so a cosmetic product cannot claim a medical outcome.
How long do published studies run?
Most topical studies are short, commonly measured in weeks, and enrol small numbers of participants. That design can detect changes in measured skin properties but cannot establish long-term outcomes.
Does GHK-Cu regrow hair?
The hair evidence is much weaker than the marketing suggests. There are laboratory and small exploratory reports, and there is no body of large controlled trials supporting it as a hair-regrowth therapy.
Can I combine it with a retinoid or vitamin C?
That is a formulation and tolerance question worth raising in a consultation. Combining active topicals can increase irritation, and product order and concentration both matter.
This page is educational. Nothing here can be ordered from this page and nothing here is a prescription or medical advice. Compounded preparations are not FDA-approved. Talk with a GOAL.MD physician at goal.md/intake or call or text 314-907-3103.
Medically reviewed by Dr. Michael Mimlitz, MD (NPI 1508891870), Chief Physician of GOAL.MD. Last reviewed 2026-08-12.